Pregnancy: Triptorelin should not be used during pregnancy since concurrent use of GnRH agonists is associated with a theoretical risk of abortion or foetal abnormality. Prior to treatment, potentially fertile women should be examined carefully to exclude pregnancy. Non-hormonal methods of contraception should be employed during therapy until menses resume.
3.75 mg: Pregnancy should be excluded before Diphereline is prescribed including before use infertility treatment.
When triptorelin is used in this setting, there is no clinical evidence to suggest a causal connection between triptorelin and any subsequent abnormalities of oocyte development or pregnancy or outcome.
11.25 mg: Pregnancy should be excluded before Diphereline P.R is prescribed.
Breast-feeding: Triptorelin should not be used during breast-feeding.